As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk an

Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of

Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in develo

Publication presented concurrently with oral presentation at American Diabetes Association's 86th Sc

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinic

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking T

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on meta

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targ

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centere

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend

Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., L

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.35) per share which met the an

Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight lo

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR)

Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company develo

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin

Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101

Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored AD

Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment,

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

https://www.barrons.com/articles/structure-therapeutics-weight-loss-pill-trial-stock-93dba470

Structure Therapeutics' Phase 2 ACCESS II trial shows up to 16.3% placebo-adjusted weight loss f

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market O

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.36) per share which beat the a

https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1